NCT00114062

Study to Treat Uveitis Associated Macular Edema

A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose Ranging Pilot Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Uveitis Associated Macular Edema

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether denufosol tetrasodium (INS37217) Intravitreal Injection is well tolerated and has the potential to treat uveitis associated macular edema.

Detailed description

Denufosol tetrasodium (INS37217) Intravitreal Injection may provide clinical benefit in treatment of uveitis associated macular edema (UME) by reducing retinal thickness as measured by OCT and possibly enabling recovery of vision loss associated with UME. Denufosol tetrasodium may also reverse the fluid accumulation of UME.

Conditions

• Cystoid Macular Edema
• Uveitis

Interventions

Type	Name	Description
DRUG	denufosol tetrasodium (INS37217) Intravitreal Injection

Timeline

• Start date: 2005-09-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2005-06-14
• Last updated: 2016-11-29